Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. An Overview of Antibody Drug Conjugate (ADC)
3.2. Key Components of ADCs
3.2.1. Cytotoxin Payloads
3.3. Key Steps in ADC Manufacturing
3.3.1. Technical Challenges in ADC Manufacturing
3.3.2. Need Outsourcing

3.4. Need for Contract Manufacturing of ADC Payloads / Warheads
3.5. Guidelines for Selecting a Suitable Partner for Cytotoxic Drugs Manufacturing
3.6. Regulatory Considerations for Cytotoxic Drugs Manufacturing
3.7. ADC Payloads / Warheads: Future Outlook

4. MARKET OVERVIEW
4.1. ADC Payloads / Warheads: List of Products and Services
4.1.1. Analysis by Type of Payload
4.1.2. Analysis by Microtubule Inhibitors
4.1.3. Analysis by DNA Damaging Agents
4.1.4. Analysis by Topoisomerase Inhibitors
4.2. ADC Payloads / Warheads: List of Developers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Location of Headquarters
4.2.3. Analysis by Company Size

5. COMPANY PROFILES
5.1. Abzena
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Developments
5.1.4. Future Outlook
5.2. MabPlex
5.2.1. Company Overview
5.2.2. Product Portfolio

5. 2.3. Recent Developments

5. 2.4. Future Outlook
5.3. Levena Biopharma
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments
5.3.4. Future Outlook
5.4. NJ Bio
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments
5.4.4. Future Outlook
5.5. Novasep
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments
5.5.4. Future Outlook
5.6. STA Pharmaceutical (a subsidiary of WuXi AppTec)
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.3. Recent Developments
5.6.4. Future Outlook
5.7. Synaffix
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.3. Recent Developments
5.7.4. Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS
6.1. ADC Payloads / Warheads: List of Partnerships and Collaborations
6.1.1. Analysis by Year of Partnership
6.1.2. Analysis by Type of Partnership
6.1.3. Analysis by Year and Type of Partnership
6.1.4. Analysis by Type of Partner and Type of Partnership
6.1.5. Most Active Players: Analysis by Number of Partnerships
6.1.6. Analysis by Intercontinental and Intracontinental Agreements

7. RECENT EXPANSIONS
7.1. ADC Payloads / Warheads: List of Recent Expansions
7.2. Cumulative Year-wise Trend
7.3. Analysis by Type of Expansion
7.4. Analysis by Year and Type of Expansion
7.5. Analysis by Location of Facility and Type of Expansion
7.6. Analysis by Location of Facility and Amount Invested
7.7. Industry Players: Analysis by Type of Expansion
7.8. Leading Players: Analysis by Amount Invested

8. FUNDING AND INVESTMENT ANALYSIS
8.1. ADC Payloads / Warheads: List of Funding and Investment
8.2. Analysis by Year of Investment
8.3. Analysis by Amount Funded
8.4. Analysis by Type of Funding
8.5. Analysis by Type of Funding and Cumulative Amount Invested
8.6. Geographical Analysis by Total Amount Invested
8.7. Most Active Players: Analysis by Amount Invested
8.8. Most Active Players: Analysis by Amount Raised

9. PATENT ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. ADC Payloads / Warheads: Patent Analysis
9.2.1. Analysis by Publication Year
9.2.2. Analysis by Type of Patent and Publication Year
9.2.3. Analysis by Type of Patent
9.2.4. Analysis by Geography
9.3.5. Analysis by CPC Symbols
9.2.6. Word Cloud: Emerging Focus Areas
9.2.7. Analysis by Type of Organization
9.2.8. Leading Industry Players: Analysis by Number of Patents
9.2.9. Leading Individual Assignees: Analysis by Number of Patents
9.2.10. ADC Payloads / Warheads: Patent Benchmarking Analysis
9.2.10.1. Analysis by Patent Valuation

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. ADC Therapeutics: Overall Annual Demand
10.3.1. ADC Payloads / Warheads: Annual Commercial Demand
10.3.1.1. Analysis by Payload Category
10.3.1.2. Analysis by Type of Payload
10.3.2. ADC Payloads / Warheads: Annual Clinical Demand
10.3.2.1. Analysis by Payload Category
10.3.2.2. Analysis by Type of Payload

11. CASE STUDY: ADC THERPEUTICS
11.1. Antibody Drug Conjugate: Development Pipeline
11.1.1. Analysis by Phase of Development
11.1.2. Analysis by Therapeutic Area
11.1.3. Analysis by Line of Treatment
11.1.4. Analysis by Dosing Regimen
11.1.5. Analysis by Target Antigen
11.1.6. Analysis by Antibody Isotype
11.1.7. Analysis by Linker Type
11.1.8. Analysis by Payload Category
11.1.9. Analysis by Type of Payload / Warhead

12. CASE STUDY: ADC CONTRACT MANUFACTURING ORGANIZATIONs
12.1. ADC Contract Manufacturing: List of Service Providers
12.1.1. Analysis by Type of Service Offered
12.1.2. Analysis by Other Service Offered
12.1.3. Analysis by Scale of Operation
12.2. ADC Contract Manufacturing Service Providers: Information on Service(s) Offered
12.3. ADC Contract Manufacturing Service Providers: Information on Other Service(s) Offered
12.4. ADC Contract Manufacturing Service Providers: Information on Scale of Operation
12.5. ADC Contract Manufacturing Service Providers: Information on Location of Manufacturing Facilities

13. MARKET FORECAST
13.1. Key Assumptions and Forecast Methodology
13.2. Global Market Forecast, Till 2035
13.3. Overall ADC Payloads / Warheads Market: Commercial Opportunity
13.3.1. Analysis by Payload Category
13.3.2. Analysis by Type of Payload
13.4. Overall ADC Payloads / Warheads Market: Clinical Opportunity
13.4.1. Analysis by Payload Category
13.4.2. Analysis by Type of Payload

14. EXECUTIVE INSIGHTS
14.1. Novasep
14.1.1. Company Snapshot
14.1.2. Interview Transcript: Kevin Daley (Market Director)
14.2. Synaffix
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Floris Van Delft (Founder and Chief Scientific Officer)

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS